Opaganib - RedHill Biopharma
Alternative Names: ABC-294640; YELIVALatest Information Update: 24 Oct 2024
At a glance
- Originator Apogee Biotechnology Corporation
- Developer Apogee Biotechnology Corporation; Medical University of South Carolina; RedHill Biopharma; University of Louisville
- Class Adamantanes; Amides; Anti-inflammatories; Antihypoglycaemics; Antineoplastics; Antirheumatics; Antithrombotics; Antivirals; Chlorobenzenes; Obesity therapies; Pyridines; Small molecules
- Mechanism of Action Sphingosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer; Inflammation
Highest Development Phases
- Phase II/III COVID-19 pneumonia
- Phase II Cholangiocarcinoma; Prostate cancer
- Preclinical Acute radiation syndrome; COVID 2019 infections; Ebola virus infections; Influenza A virus infections; Obesity; Radiation injuries; Renal fibrosis; SARS-CoV-2 acute respiratory disease; Type 2 diabetes mellitus
- Suspended Liver cancer
- No development reported Cancer; Inflammatory bowel diseases; Osteoarthritis; Rheumatoid arthritis; Solid tumours
- Discontinued Multiple myeloma
Most Recent Events
- 22 Oct 2024 RedHill Biopharma and Duke University School of Medicine agree to co-develop Opaganibin for Lung injury (Phosgene inhalation injury)
- 30 Sep 2024 9426589: Patent protection for Identification of biomarkers for coronavirus pneumonia and post hoc data, no updates
- 26 Aug 2024 Opaganib receives Orphan Drug status for neuroblastoma in USA